Showing results (311-320 of 501) with videos related to
Sort By:
Pageof 51
NPJ Genomic Medicine|September 22, 2021
Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT SignaturesNicholas R Rydzewski, Erik Peterson, Joshua M Lang, et al.Nature Communications|January 16, 2021
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repairAyesha A Shafi, Chris M McNair, Jennifer J McCann, et al.Nature Genetics|January 20, 2015
The landscape of long noncoding RNAs in the human transcriptomeMatthew K Iyer, Yashar S Niknafs, Rohit Malik, et al.Practical Radiation Oncology|January 7, 2018
A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of lifeWilliam C Jackson, Robert T Dess, Dale W Litzenberg, et al.BJU International|March 25, 2016
Independent surgical validation of the new prostate cancer grade-grouping systemDaniel E Spratt, Adam I Cole, Ganesh S Palapattu, et al.Cancer Research|December 17, 2015
Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted TherapyAndrew S McDaniel, Daniel H Hovelson, Andi K Cani, et al.International Journal of Radiation Oncology, Biology, Physics|March 1, 2018
Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate CancerRobert T Dess, Theresa P Devasia, Nima Aghdam, et al.European Urology Oncology|March 3, 2023
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate CancerAli Sabbagh, Samuel L Washington, Derya Tilki, et al.European Urology Oncology|March 4, 2023
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission TomographyClayton P Smith, James A Proudfoot, Paul C Boutros, et al.The Lancet. Oncology|December 3, 2014
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1John R Prensner, Shuang Zhao, Nicholas Erho, et al.Pageof 51